Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome

Area of Science:

• Immunology
• Pediatric Hematology
• Genetic Disorders

Background:

• Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency.
• Identifying distinct clinical phenotypes within WAS is crucial for timely intervention.
• Previous studies highlight varied disease severity and progression in WAS patients.

Purpose of the Study:

• To identify a subgroup of infants with Wiskott-Aldrich syndrome (WAS) presenting with early-onset, severe manifestations.
• To characterize the clinical features and genetic basis of this WAS subgroup.
• To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) in this high-risk population.

Main Methods:

• Nationwide database analysis of 160 Wiskott-Aldrich syndrome patients.
• Retrospective analysis of infants with an Ochs score of 5 before age 2.
• Genetic analysis for WAS protein mutations and confirmation of protein absence.
• Evaluation of allogeneic hematopoietic stem cell transplantation outcomes.

Main Results:

• A distinct subgroup of 26 infants (55%) with Wiskott-Aldrich syndrome (WAS) was identified with an Ochs score of 5 before age 2.
• This subgroup frequently exhibited severe refractory thrombocytopenia, autoimmune hemolytic anemia, vasculitis, and in one case, two distinct cancers.
• Absence of WAS protein was confirmed in tested patients, and HSCT was successful in 17 of 22 patients, though 4 died before transplantation.

Conclusions:

• A subgroup of Wiskott-Aldrich syndrome (WAS) patients with early-onset, life-threatening manifestations has been identified.
• Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative strategy for this WAS subgroup.
• Early HSCT, even without a fully matched donor, is recommended for improved prognosis in these infants.